血液中花生四烯酸乙醇胺含量与精神分裂症发病机制的研究

Study on anandamide levels in peripheral blood of schizophrenic patients

目的分析精神分裂症患者血液中花生四烯酸乙醇胺(AEA)含量的变化,探讨与精神分裂症病理之间的联系。方法采集56例精神分裂症患者静脉血液样本,应用高效液相色谱法(HPLC)柱前衍生化测定精神分裂症患者血液样品中AEA含量变化;并与40例健康者血液中AEA含量进行比较。结果精神分裂症患者血液中AEA含量明显高于对照组[(23.87±1.32)ng/mL vs(11.26±0.81 ng/mL)],两组样本间差异有统计学意义(P<0.05)。结论精神分裂症患者症状活跃期间血液中AEA含量增高,可能与精神分裂症的发病机制有关,该结果为精神分裂疾病药物研发提供新思路。

【Objective】 To investigate the changes of the anandamide in peripheral blood from patients with schizophrenia. 【Methods】 Using high performance liquid chromatography（HPLC） to measure anandamide levels in serum from 56 patients with schizophrenia.40 healthy controls were measured as standard for comparison. 【Results】 The endocannabinoid anandamide levels were significantly higher in the blood of patients with acute schizophrenia than in healthy volunteers. During schizophrenia, AEA levels were 2.0 times normal term levels（23.87 ± 1.32 ng/mL vs 11.26 ± 0.81 ng/mL, P 〈0.05）. 【Conclusion】 AEA increasing in the blood of patients with schizophrenia indicate that ECS endocannabinoid signaling be altered during the phase of schizophrenia. Anandamidergic activity have some relation with psychotic mechanism which suggests that anandamide might play an important role in schizophrenia. In this context, there are lots of new CB ligands therapeutic drug maybe effect in schizophrenia and schizoaffective disorders.